- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | NeOnc Technologies redeems all $6M Series A preferred stock | 1 | Seeking Alpha | ||
| Do | 24/7 Market News and NeOnc Technology: NeOnc Eliminates Major Dilution Risk as Clinical Story Accelerates | 1 | GlobeNewswire (USA) | ||
| Do | NeOnc Technologies Holdings, Inc.: NeOnc Technologies Redeems All Outstanding Series A Convertible Preferred Stock and Eliminates Related Potential Dilution | 135 | GlobeNewswire (Europe) | CALABASAS, Calif., Sept. 17, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) ("NeOnc" or the "Company"), a multi-Phase 2 clinical-stage biopharmaceutical company developing... ► Artikel lesen | |
| Mi | 24/7 Market News and NeOnc Technology: NeOnc's $629K Insider Buying Spree Follows Breakthrough Data and Now All Eyes Turn to the FDA | 2 | GlobeNewswire (USA) | ||
| Mi | NeOnc CEO purchases additional shares following trial results | 1 | Investing.com | ||
| Di | Investors Tape and NeOnc: Investor Determination to Beat Cancer Puts NeOnc's Novel Therapies and Patented Platform in Focus | 2 | GlobeNewswire (USA) | ||
| NEONC TECHNOLOGIES Aktie jetzt für 0€ handeln | |||||
| Mo | 24/7 Market News and NeOnc Technology: Insiders Continue Buying, as NeOnc Moves NEO100 Toward Its Next Regulatory Test | 1 | GlobeNewswire (USA) | ||
| 10.09. | NEONC TECHNOLOGIES HOLDINGS, INC. - 8-K, Current Report | - | SEC Filings | ||
| 09.09. | 24/7 Market News and NeOnc Technology: NeOnc Raises $15 Million At Market Adding Fuel to the Strong NEO100 Data | 2 | GlobeNewswire (USA) | ||
| 08.09. | 24/7 Market News and NeOnc Technology: NeOnc' Phase 2 Data Could Put Cancer on the Ropes | 1 | GlobeNewswire (USA) | ||
| 28.08. | 24/7 Market News and NeOnc Technology: NeOnc's Phase 2A Success Could Set the Stage for Something Much Bigger | 2 | GlobeNewswire (USA) | ||
| 26.08. | 24/7 Market News and NeOnc Technology: NeOnc's Clinical Story Is Now the Main Event | 2 | GlobeNewswire (USA) | ||
| 20.08. | NEONC TECHNOLOGIES HOLDINGS, INC. - 8-K, Current Report | 3 | SEC Filings | ||
| 18.08. | 24/7 Market News and NeOnc Technology: NeOnc Technologies- Talk Is Cheap, Insider Buying Isn't | 1 | GlobeNewswire (USA) | ||
| 17.08. | 24/7 Market News and NeOnc Technology: NTHI's Nasdaq Advantage Takes on New Meaning After Its Breakthrough Phase 2a Results | 1 | GlobeNewswire (USA) | ||
| 13.08. | Stonegate, Inc.: Stonegate Capital Partners Updates Coverage on NeOnc Technologies Holdings, Inc. (NTHI) 2Q26 | 453 | Newsfile | Dallas, Texas--(Newsfile Corp. - August 13, 2026) - NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI). Stonegate Capital Partners Updates Coverage on NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI).... ► Artikel lesen | |
| 13.08. | 24/7 Market News and NeOnc Technology: The Nose Knows: Why NeOnc's Patent Portfolio Could Make NTHI More Than a One-Drug Biotech | 4 | GlobeNewswire (USA) | ||
| 12.08. | Investors Tape and NeOnc: Targeting The Mutant: NTHI's NEO100 Data Could Open a New Front in the Fight Against Brain Cancer | 3 | GlobeNewswire (USA) | ||
| 12.08. | NeOnc reports phase 2a glioma trial meets primary endpoint | 4 | Investing.com | ||
| 12.08. | WallStreet-PR: NeOnc's NEO100 Phase 2a Brain Cancer Study Beats Historical Benchmark by Nearly 2.5x | 423 | Newsfile | Houston, Texas--(Newsfile Corp. - August 12, 2026) - NeOnc Technologies Holdings (NASDAQ: NTHI) reported encouraging Phase 2a results for intranasal NEO100 in patients with recurrent IDH1-mutant... ► Artikel lesen |
1 2 3 4 Weiter >>
71 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVAVAX | 8,670 | -1,37 % | Novavax: Langfristige Aussichten im Spannungsfeld von Innovation und Konkurrenz | ||
| INOVIO PHARMACEUTICALS | 1,077 | +9,40 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Second Quarter 2026 Financial Results and Recent Business Highlights | U.S. Food and Drug Administration (FDA) review of Biologics License Application (BLA) for INO-3107 as a treatment for Recurrent Respiratory Papillomatosis (RRP)... ► Artikel lesen | |
| INFLARX | 1,842 | +0,99 % | Klinische Daten geben InflaRx NV neuen Schub: Der Weg über 2 EUR | ||
| INTELLIA THERAPEUTICS | 10,360 | -2,08 % | Cathie Wood's ARK sells Twist Bioscience stock, buys more Intellia | ||
| EDITAS MEDICINE | 2,370 | +0,85 % | Editas Medicine, Inc.: Editas Medicine Appoints Dan Ory, M.D., as Chief Medical Officer | Experienced biotechnology executive with more than 25 years of leadership in cardiovascular and genetic medicine to lead clinical development Appointment strengthens executive leadership team as... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 7,490 | 0,00 % | BioCryst Pharmaceuticals, Inc.: BioCryst Announces Approval of ORLADEYO for Pediatric HAE Patients in Japan | - Expands availability of the first and only oral prophylactic therapy for patients with HAE ages 2 to RESEARCH TRIANGLE PARK, N.C., Aug. 25, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc.... ► Artikel lesen | |
| NUREXONE BIOLOGIC | 0,385 | -2,78 % | Bis zu 5,4 Millionen US-Dollar pro Patient: Warum Medtronic, Globus Medical und NurExone an derselben Verletzung ansetzen | ||
| ABIVAX | 90,75 | -2,89 % | Abivax Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call | ||
| BIOMARIN PHARMACEUTICAL | 56,08 | +0,75 % | BioMarin Pharmaceutical Inc.: BioMarin Announces Appointment of Robert Plenge, M.D., Ph.D., Chief Research Officer of Bristol Myers Squibb, to Board of Directors | SAN RAFAEL, Calif., Sept. 14, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced that the company has appointed Robert Plenge, M.D., Ph.D.... ► Artikel lesen | |
| IBIO | 1,109 | +1,46 % | iBio stock initiated at buy by H.C. Wainwright with $7 target | ||
| GERON | 1,159 | +2,79 % | Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| IMMUNITYBIO | 7,380 | -0,27 % | XETR NEW INSTRUMENTS AVAILABLE ON XETRA - 04.06.2026 | Folgende Wertpapiere werden in den Handel an folgenden Handelsplätzen (MIC Code) im Quotation Board an der Frankfurter Wertpapierbörse (FWB) aufgenommen. Die Notierung an anderen Handelsplätzen im Quotation... ► Artikel lesen | |
| IMMATICS | 7,525 | +0,40 % | Immatics Announces $150 Million Underwritten Offering | Houston, Texas and Tuebingen, Germany, August 25, 2026 - Immatics N.V. (NASDAQ: IMTX, "Immatics" or the "Company"), the global leader in precision targeting of PRAME with multiple clinical-stage programs... ► Artikel lesen | |
| MYRIAD GENETICS | 3,368 | 0,00 % | Myriad Genetics, Inc.: Myriad Genetics Appoints Vishal Sikri Executive Vice President - Commercial | SALT LAKE CITY, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that Vishal Sikri has been... ► Artikel lesen | |
| MANNKIND | 3,073 | 0,00 % | MannKind and Rose Pharma Inc Enter Licensing and Collaboration Agreement to Develop an Inhaled Rapid-Acting, Short-Duration GLP-1 for Weight Management | Collaboration combines Rose Pharma investigational rapid-acting GLP-1 receptor agonist with MannKind's Technosphere- inhalation technologyMannKind to receive an equity interest and potential royalties... ► Artikel lesen |
Das Unternehmen NEONC TECHNOLOGIES HOLDINGS INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 3,260 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NEONC TECHNOLOGIES HOLDINGS INC finden Sie auf Wallstreet Online.